VIRAGEN INC
10-Q, EX-27.1, 2000-11-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: VIRAGEN INC, 10-Q, EX-11, 2000-11-14
Next: QUIDEL CORP /DE/, 10-Q, 2000-11-14



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JUN-30-2001
<PERIOD-START>                             JUL-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                       8,811,728
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             9,205,166
<PP&E>                                       6,243,123
<DEPRECIATION>                               1,398,516
<TOTAL-ASSETS>                              14,122,511
<CURRENT-LIABILITIES>                        1,352,447
<BONDS>                                         40,556
                                0
                                      2,650
<COMMON>                                       937,596
<OTHER-SE>                                  11,391,761
<TOTAL-LIABILITY-AND-EQUITY>                14,122,511
<SALES>                                              0
<TOTAL-REVENUES>                               322,973
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                             2,142,406
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              15,603
<INCOME-PRETAX>                             (1,672,816)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                         (1,672,816)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                (1,672,816)
<EPS-BASIC>                                      (0.02)
<EPS-DILUTED>                                    (0.02)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission